Key Data Files for this Active Pharmaceutical Ingredient:

Drug Master Files, 21 CFR, and other industry portals Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… Targretin (bexarotene) Gel, 1%, Ligand NDA 21-056 6/28/00 7/24/00 7/24/00 7/12/01 Targretin Indications: for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies. Targretin (bexarotene) capsules, 75 mg, Ligand NDA 21-055/S2 & S3 4/21/03 4/28/03 Targretin (bexarotene) capsules, 75 mg [Patient Labeling] Ligand NDA 21-055 12/29/99 1/3/00 1/3/00 4/11/02 Targretin Indication: Targretin (bexarotene) capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.   For the latest approval information, locate this drug using this index.